Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization.
BACKGROUND
Familial combined hypolipidemia causes a global reduction of plasma lipoproteins. Its clinical correlates and metabolic implications have not been well defined.


OBJECTIVE
The objective of the study was to investigate the genetic, clinical, and metabolic characteristics of a cohort of subjects with familial combined hypolipidemia.


METHODS
The design of the study included candidate gene screening and the comparison of the clinical and metabolic characteristics between carrier and noncarrier individuals.


METHODS
The study was conducted in a general community.


METHODS
Participants in the study included individuals belonging to nine families with familial combined hypolipidemia identified in a small town (Campodimele) as well as from other 352 subjects living in the same community.


METHODS
Serum concentrations of lipoproteins, Angiopoietin-like 3 (Angptl3) proteins, and noncholesterol sterols were measured.


RESULTS
The ANGPTL3 S17X mutation was found in all probands, 20 affected family members, and 32 individuals of the community. Two additional frame shift mutations, FsE96del and FsS122, were also identified in two hypocholesterolemic individuals. Homozygotes for the ANGPTL3 S17X mutation had no circulating Angptl3 and a marked reduction of all plasma lipids (P < 0.001). Heterozygotes had 42% reduction in Angptl3 level compared with noncarriers (P < 0.0001) but a significant reduction of only total cholesterol and high-density lipoprotein cholesterol. No differences were observed in the plasma noncholesterol sterols between carriers and noncarriers. No association between familial combined hypolipidemia and the risk of hepatic or cardiovascular diseases were detected.


CONCLUSIONS
Familial combined hypolipidemia segregates as a recessive trait so that apolipoprotein B- and apolipoprotein A-I-containing lipoproteins are comprehensively affected only by the total deficiency of Angptl3. Familial combined hypolipidemia does not perturb whole-body cholesterol homeostasis and is not associated with adverse clinical sequelae.
Department of Internal Medicine and Medical Specialties, Atherosclerosis Unit, Sapienza University of Rome, 00161 Rome, Italy.
Ilenia
I
Minicocci
Anna
A
Montali
Marius Robert
MR
Robciuc
Fabiana
F
Quagliarini
Vincenzo
V
Censi
Giancarlo
G
Labbadia
Claudia
C
Gabiati
Giovanni
G
Pigna
Maria Laura
ML
Sepe
Fabio
F
Pannozzo
Dieter
D
Lütjohann
Sergio
S
Fazio
Matti
M
Jauhiainen
Christian
C
Ehnholm
Marcello
M
Arca
D000328:Adult; D000368:Aged; D000091303:Angiopoietin-Like Protein 3; D000075802:Angiopoietin-like Proteins; D042682:Angiopoietins / Q000097:blood / Q000235:genetics*; D016632:Apolipoprotein A-I / Q000097:blood / Q000378:metabolism; D001055:Apolipoproteins B / Q000097:blood / Q000378:metabolism; D016022:Case-Control Studies; D002784:Cholesterol / Q000097:blood; D015331:Cohort Studies; D004252:DNA Mutational Analysis; D005190:Family; D005260:Female; D005838:Genotype; D006801:Humans; D007009:Hypolipoproteinemias / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics*; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000502:physiology; D010375:Pedigree; D010641:Phenotype
C479896:ANGPTL3 protein, human; D000091303:Angiopoietin-Like Protein 3; D000075802:Angiopoietin-like Proteins; D042682:Angiopoietins; D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D002784:Cholesterol